Skip Navigation


JAC Advance Access originally published online on July 15, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/229    most recent
dkg321v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (211)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jacobs, M. R.
Right arrow Articles by the Alexander Project Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, M. R.
Right arrow Articles by the Alexander Project Group,
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 229-246
© 2003 The British Society for Antimicrobial Chemotherapy

The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

Michael R. Jacobs1,*, David Felmingham2, Peter C. Appelbaum3, Reuben N. Grüneberg2 and the Alexander Project Group§

1 Department of Pathology, Case Western Reserve University and University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106; 3 Hershey Medical Center, Hershey, PA, USA; 2 GR Micro, London, UK

Received 24 May 2002; returned 1 July 2002; revised 30 April 2003; accepted 7 May 2003

Objectives: The Alexander Project is a continuing surveillance study, begun in 1992, examining the susceptibility of pathogens involved in adult community-acquired respiratory tract infections (CARTI) to a range of antimicrobial agents.

Materials and methods: This study tested the susceptibility of isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected between 1998 and 2000 to 23 antimicrobials. Minimum inhibitory concentrations of agents were determined using the broth microdilution method and interpreted according to NCCLS and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

Results: In total, 8882 isolates of S. pneumoniae, 8523 isolates of H. influenzae and 874 isolates of M. catarrhalis were collected during 1998–2000 from centres in 26 countries. The world-wide prevalence of penicillin resistance (penicillin MICs >= 2 mg/L) in isolates of S. pneumoniae was 18.2% over the study period, and the prevalence of macrolide resistance (erythromycin MICs >= 1 mg/L) in this pathogen was 24.6%. Over the study period, macrolide resistance exceeded penicillin resistance in 19 of the 26 countries included in the study. Of the non-fluoroquinolone agents, the only oral agents to which over 90% of S. pneumoniae isolates were susceptible at both NCCLS and PK/PD breakpoints were amoxicillin (95.1%) and co-amoxiclav (95.5–97.9%). The prevalence of fluoroquinolone-resistant S. pneumoniae (ofloxacin MICs >= 8 mg/L) was 1.1%. Gemifloxacin was the most potent fluoroquinolone tested against S. pneumoniae (99.9% susceptible). In isolates of H. influenzae, ß-lactamase production was 16.9%, whereas the prevalence of ß-lactamase-negative, ampicillin-resistant strains was low (0.2%). ß-Lactamase production in M. catarrhalis world-wide remained high over the period studied (92.1%). Using PK/PD breakpoints, the most active non-fluoroquinolone agents against H. influenzae were ceftriaxone (100% susceptible), cefixime (99.8%) and co-amoxiclav (98.1–99.6%). Co-amoxiclav, cefdinir and cefixime (100%) were the most active ß-lactams against M. catarrhalis. Both H. influenzae and M. catarrhalis were highly susceptible to the fluoroquinolones.

Conclusions: These data demonstrate the continued evolution of and geographical variation in bacterial resistance and highlight the need for appropriate prescribing of antimicrobials in CARTI, using agents with adequate activity, based on local susceptibility profiles and PK/PD parameters.

Keywords: surveillance, antimicrobial resistance, community-acquired respiratory tract infection, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

* Corresponding author. Tel: +1-216-844-3484; Fax: +1-216-844-5601; E-mail: mrj6{at}po.cwru.edu

§ The Alexander Study group participants are listed in the Acknowledgements.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
S. Garcia-Cobos, J. Campos, E. Cercenado, F. Roman, E. Lazaro, M. Perez-Vazquez, F. de Abajo, and J. Oteo
Antibiotic Resistance in Haemophilus influenzae Decreased, except for {beta}-Lactamase-Negative Amoxicillin-Resistant Isolates, in Parallel with Community Antibiotic Consumption in Spain from 1997 to 2007
Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2760 - 2766.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
S. Ladhani, P. T. Heath, M. E. Ramsay, and M. P. E. Slack
Changes in antibiotic resistance rates of invasive Haemophilus influenzae isolates in England and Wales over the last 20 years
J. Antimicrob. Chemother., July 28, 2008; (2008) dkn274v1.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Smith, L. M. Ednie, P. C. Appelbaum, S. Hawser, and S. Lociuro
Antistreptococcal Activity of AR-709 Compared to That of Other Agents
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2279 - 2282.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Takahata, Y. Kato, Y. Sanbongi, K. Maebashi, and T. Ida
Comparison of the Efficacies of Oral {beta}-Lactams in Selection of Haemophilus influenzae Transformants with Mutated ftsI Genes
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1880 - 1883.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
D. E. Karageorgopoulos MD, K. P. Giannopoulou MD, A. P. Grammatikos MD MSc, G. Dimopoulos MD, and M. E. Falagas MD DSc
Fluoroquinolones compared with {beta}-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials
Can. Med. Assoc. J., March 25, 2008; 178(7): 845 - 854.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Balsalobre and A. G. de la Campa
Fitness of Streptococcus pneumoniae Fluoroquinolone-Resistant Strains with Topoisomerase IV Recombinant Genes
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 822 - 830.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Kosowska-Shick, C. Clark, K. Credito, B. Dewasse, L. Beachel, L. Ednie, and P. C. Appelbaum
In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 748 - 752.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Clark, K. Smith, L. Ednie, T. Bogdanovich, B. Dewasse, P. McGhee, and P. C. Appelbaum
In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 77 - 84.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
S. G. Tristram and J. G. Burdach
Effect of cloned inhibitor-resistant TEM {beta}-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1151 - 1154.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. L. Clark, K. Kosowska-Shick, L. M. Ednie, and P. C. Appelbaum
Capability of 11 Antipneumococcal Antibiotics To Select for Resistance by Multistep and Single-Step Methodologies
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4196 - 4201.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. Canut, J. E. Martin-Herrero, A. Labora, and H. Maortua
What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model
J. Antimicrob. Chemother., September 1, 2007; 60(3): 605 - 612.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
B. Sener, F. Tunckanat, S. Ulusoy, A. Tunger, G. Soyletir, L. Mulazimoglu, N. Gurler, L. Oksuz, I. Koksal, K. Aydin, et al.
A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005
J. Antimicrob. Chemother., September 1, 2007; 60(3): 587 - 593.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Calatayud, C. Ardanuy, E. Cercenado, A. Fenoll, E. Bouza, R. Pallares, R. Martin, and J. Linares
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3240 - 3246.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A. Masood, I. Moumoulidis, and J. Panesar
Acute rhinosinusitis in adults: an update on current management
Postgrad. Med. J., June 1, 2007; 83(980): 402 - 408.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. Martin, S. Quilici, T. File, J. Garau, A. Kureishi, and M. Kubin
Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance
J. Antimicrob. Chemother., May 1, 2007; 59(5): 977 - 989.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
S. Tristram, M. R. Jacobs, and P. C. Appelbaum
Antimicrobial Resistance in Haemophilus influenzae
Clin. Microbiol. Rev., April 1, 2007; 20(2): 368 - 389.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. Izdebski, E. Sadowy, J. Fiett, P. Grzesiowski, M. Gniadkowski, and W. Hryniewicz
Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1155 - 1163.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
L. Hogberg, P. Geli, H. Ringberg, E. Melander, M. Lipsitch, and K. Ekdahl
Age- and Serogroup-Related Differences in Observed Durations of Nasopharyngeal Carriage of Penicillin-Resistant Pneumococci
J. Clin. Microbiol., March 1, 2007; 45(3): 948 - 952.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. Sadowy, R. Izdebski, A. Skoczynska, P. Grzesiowski, M. Gniadkowski, and W. Hryniewicz
Phenotypic and Molecular Analysis of Penicillin-Nonsusceptible Streptococcus pneumoniae Isolates in Poland
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 40 - 47.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Ardanuy, A. Fenoll, S. Berron, L. Calatayud, J. Linares, and the Spanish Pneumococcal Infection Study Network
Increase of the M Phenotype among Erythromycin-Resistant Streptococcus pneumoniae Isolates from Spain Related to the Serotype 14 Variant of the Spain9V-3 Clone.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3162 - 3165.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
Y. Sanbongi, T. Suzuki, Y. Osaki, N. Senju, T. Ida, and K. Ubukata
Molecular Evolution of {beta}-Lactam-Resistant Haemophilus influenzae: 9-Year Surveillance of Penicillin-Binding Protein 3 Mutations in Isolates from Japan.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2487 - 2492.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
O. Schussler, M. Alifano, H. Dermine, S. Strano, A. Casetta, S. Sepulveda, A. Chafik, S. Coignard, A. Rabbat, and J.-F. Regnard
Postoperative Pneumonia after Major Lung Resection
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1161 - 1169.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum
Antipneumococcal Activity of Dalbavancin Compared to Other Agents
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
T. Luxameechanporn, V. Kirtsreesakul, J. Klemens, P. Khoury, K. Thompson, and R. M. Naclerio
Evaluation of Importance of Toll-like Receptor 4 in Acute Streptococcus pneumoniae Sinusitis in Mice
Arch Otolaryngol Head Neck Surg, November 1, 2005; 131(11): 1001 - 1006.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. P. Cober and C. E Johnson
Otitis Media: Review of the 2004 Treatment Guidelines
Ann. Pharmacother., November 1, 2005; 39(11): 1879 - 1887.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. Rantala, S. Huikko, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan
Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4180 - 4184.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. J. Stanhope, S. L. Walsh, J. A. Becker, M. J. Italia, K. A. Ingraham, M. N. Gwynn, T. Mathie, J. A. Poupard, L. A. Miller, J. R. Brown, et al.
Molecular Evolution Perspectives on Intraspecific Lateral DNA Transfer of Topoisomerase and Gyrase Loci in Streptococcus pneumoniae, with Implications for Fluoroquinolone Resistance Development and Spread
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4315 - 4326.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
W. K. Lee and B. W. Y. Young
Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae
J. Antimicrob. Chemother., September 1, 2005; 56(3): 603 - 605.
[Full Text] [PDF]


Home page
ChestHome page
K. Weiss and G. S. Tillotson
The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia
Chest, August 1, 2005; 128(2): 940 - 946.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. R. Reinert, S. Reinert, M. van der Linden, M. Y. Cil, A. Al-Lahham, and P. Appelbaum
Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2903 - 2913.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. J. Ferrandiz, C. Ardanuy, J. Linares, J. M. Garcia-Arenzana, E. Cercenado, A. Fleites, A. G. de la Campa, and the Spanish Pneumococcal Infection Study Network
New Mutations and Horizontal Transfer of rpoB among Rifampin-Resistant Streptococcus pneumoniae from Four Spanish Hospitals
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2237 - 2245.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. P. Heilmann, C. L. Rice, A. L. Miller, N. J. Miller, S. E. Beekmann, M. A. Pfaller, S. S. Richter, and G. V. Doern
Decreasing Prevalence of {beta}-Lactamase Production among Respiratory Tract Isolates of Haemophilus influenzae in the United States
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2561 - 2564.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. Perez-Trallero, C. Garcia-de-la-Fuente, C. Garcia-Rey, F. Baquero, L. Aguilar, R. Dal-Re, J. Garcia-de-Lomas, and the Spanish Surveillance Group for Respiratory Pat
Geographical and Ecological Analysis of Resistance, Coresistance, and Coupled Resistance to Antimicrobials in Respiratory Pathogenic Bacteria in Spain
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1965 - 1972.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
K. Kasahara, K. Maeda, K. Mikasa, K. Uno, K. Takahashi, M. Konishi, E. Yoshimoto, K. Murakawa, E. Kita, and H. Kimura
Clonal Dissemination of Macrolide-Resistant and Penicillin-Susceptible Serotype 3 and Penicillin-Resistant Taiwan 19F-14 and 23F-15 Streptococcus pneumoniae Isolates in Japan: a Pilot Surveillance Study
J. Clin. Microbiol., April 1, 2005; 43(4): 1640 - 1645.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
V. Berry, J. Hoover, C. Singley, and G. Woodnutt
Comparative Bacteriological Efficacy of Pharmacokinetically Enhanced Amoxicillin-Clavulanate against Streptococcus pneumoniae with Elevated Amoxicillin MICs and Haemophilus influenzae
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 908 - 915.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
M. R. M. Jimenez, J. L. M. Bellido, and J. A. Garcia Rodriguez
Risk Factors Associated with Colonization by Pneumococci with Reduced Susceptibility to Fluoroquinolones in Adult Outpatients
J. Clin. Microbiol., March 1, 2005; 43(3): 1193 - 1197.
[Abstract] [Full Text] [PDF]


Home page
CLIN PEDIATRHome page
P. C. Appelbaum
Are Cephalosporins Appropriate for the Treatment of Acute Otitis Media in This Era of Increasing Antimicrobial Resistance Among Common Respiratory Tract Pathogens?
Clinical Pediatrics, March 1, 2005; 44(2): 95 - 107.
[PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Ardanuy, F. Tubau, J. Linares, M. A. Dominguez, R. Pallares, R. Martin, and The Spanish Pneumococcal Infection Study Network
Distribution of Subclasses mefA and mefE of the mefA Gene among Clinical Isolates of Macrolide-Resistant (M-Phenotype) Streptococcus pneumoniae, Viridans Group Streptococci, and Streptococcus pyogenes
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 827 - 829.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Sethi, J. Breton, and B. Wynne
Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis
Antimicrob. Agents Chemother., January 1, 2005; 49(1): 153 - 160.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. Abbanat, G. Webb, B. Foleno, Y. Li, M. Macielag, D. Montenegro, E. Wira, and K. Bush
In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides
Antimicrob. Agents Chemother., January 1, 2005; 49(1): 309 - 315.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. R. Oggioni, F. Iannelli, S. Ricci, D. Chiavolini, R. Parigi, C. Trappetti, J.-P. Claverys, and G. Pozzi
Antibacterial Activity of a Competence-Stimulating Peptide in Experimental Sepsis Caused by Streptococcus pneumoniae
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4725 - 4732.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. Cerquetti, R. Cardines, M. Giufre, P. Mastrantonio, and on behalf of the Hi Study Group
Antimicrobial susceptibility of Haemophilus influenzae strains isolated from invasive disease in Italy
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1139 - 1143.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Dias and M. Canica
Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1035 - 1039.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
N. Bruinsma, K. G. Kristinsson, S. Bronzwaer, P. Schrijnemakers, J. Degener, E. Tiemersma, W. Hryniewicz, J. Monen, H. Grundmann, and on behalf of EARSS participants
Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1045 - 1050.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
I. Odenholt, O. Cars, and E. Lowdin
Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1062 - 1066.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
V. Matic, K. Kosowska, B. Bozdogan, L. M. Kelly, K. Smith, L. M. Ednie, G. Lin, K. L. Credito, C. L. Clark, P. McGhee, et al.
Antipneumococcal Activities of Two Novel Macrolides, GW 773546 and GW 708408, Compared with Those of Erythromycin, Azithromycin, Clarithromycin, Clindamycin, and Telithromycin
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4103 - 4112.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Kosowska, M. R. Jacobs, S. Bajaksouzian, L. Koeth, and P. C. Appelbaum
Alterations of Penicillin-Binding Proteins 1A, 2X, and 2B in Streptococcus pneumoniae Isolates for Which Amoxicillin MICs Are Higher than Penicillin MICs
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4020 - 4022.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. Powis, A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, et al.
In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3305 - 3311.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
T. M. File Jr., H. Lode, H. Kurz, R. Kozak, H. Xie, and E. Berkowitz
Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3323 - 3331.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
A. Saeed-Kothe, W. Yang, and S. D. Mills
Use of the Riboflavin Synthase Gene (ribC) as a Model for Development of an Essential Gene Disruption and Complementation System for Haemophilus influenzae
Appl. Envir. Microbiol., July 1, 2004; 70(7): 4136 - 4143.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. Rendi-Wagner, A. Georgopoulos, M. Kundi, I. Mutz, M. Mattauch, J. Nowak, A. Mikolasek, A. Vecsei, and H. Kollaritsch
Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria
J. Antimicrob. Chemother., May 1, 2004; 53(5): 826 - 831.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
Subcommittee on Management of Acute Otitis Media
Diagnosis and Management of Acute Otitis Media
Pediatrics, May 1, 2004; 113(5): 1451 - 1465.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J.-H. Song, H.-H. Chang, J. Y. Suh, K. S. Ko, S.-I. Jung, W. S. Oh, K. R. Peck, N. Y. Lee, Y. Yang, A. Chongthaleong, et al.
Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP)
J. Antimicrob. Chemother., March 1, 2004; 53(3): 457 - 463.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
I. Morrissey and G. Tillotson
Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae
J. Antimicrob. Chemother., February 1, 2004; 53(2): 144 - 148.
[Abstract] [Full Text] [PDF]


Home page